A Pilot Study to Determine the Correlation of Serum Procalcitonin Levels and Development of Sepsis in Patients Undergoing Cytoreductive Surgery
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| Contact: | Michelle Niesley, ND, MS |
| Email: | michelle.niesley@ctca-hope.com |
| Phone: | 215-537-3160 |
Serum procalcitonin levels will be considerably higher, for a longer period of time, in
patients who develop sepsis compared to patients with SIRS or those who have an
uncomplicated post-surgical recovery. Monitoring of serum procalcitonin trends will allow
for an earlier diagnosis of, and initiation of treatment for, sepsis compared to current
standard ICU methods.
patients who develop sepsis compared to patients with SIRS or those who have an
uncomplicated post-surgical recovery. Monitoring of serum procalcitonin trends will allow
for an earlier diagnosis of, and initiation of treatment for, sepsis compared to current
standard ICU methods.
Inclusion Criteria:
- Female or male person ≥ 18 years of age
- Biopsy proven carcinoma
- Scheduled for cytoreductive surgery, with or without HIPEC
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1, or 2
- Able to give informed consent for protocol participation
Exclusion Criteria:
- Participants are not able to understand or provide written informed consent
- Pre-operative anti-inflammatory medication use within 72 hours of their baseline
blood draw
- Pre-operative infection treatment with corticosteroids within 72 hours of their
baseline blood draw
- Immunosuppressive illness other than neoplasm
- Pregnant or lactating female
We found this trial at
1
site
Philadelphia, Pennsylvania 19124
Principal Investigator: Rod Flynn, MD
Phone: 215-537-3160
Click here to add this to my saved trials
